Avalo Therapeutics (NASDAQ:AVTX) Given New $22.00 Price Target at Wedbush

Avalo Therapeutics (NASDAQ:AVTX) had its target price dropped by research analysts at Wedbush from $34.00 to $22.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush‘s price objective would suggest a potential upside of 195.30% from the company’s previous close.

A number of other equities analysts have also recently weighed in on AVTX. BTIG Research decreased their price objective on shares of Avalo Therapeutics to $10.00 and set a “buy” rating for the company in a research report on Friday. Guggenheim restated a “neutral” rating on shares of Avalo Therapeutics in a research note on Friday. Wall Street Zen cut shares of Avalo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.10.

Avalo Therapeutics Trading Down 39.2%

Shares of AVTX stock opened at $7.45 on Friday. The company has a market capitalization of $399.54 million, a PE ratio of -1.70 and a beta of 0.68. The firm has a fifty day simple moving average of $16.30 and a 200-day simple moving average of $16.67. Avalo Therapeutics has a twelve month low of $6.85 and a twelve month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Equities research analysts predict that Avalo Therapeutics will post -2.95 EPS for the current year.

Insider Transactions at Avalo Therapeutics

In related news, CFO Christopher Sullivan sold 12,394 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total value of $202,394.02. Following the sale, the chief financial officer directly owned 39,900 shares in the company, valued at $651,567. This trade represents a 23.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 24,258 shares of company stock valued at $415,434. Corporate insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Braidwell LP bought a new stake in shares of Avalo Therapeutics during the second quarter valued at about $30,107,000. Seven Fleet Capital Management LP lifted its holdings in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after acquiring an additional 510,540 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after buying an additional 507,960 shares in the last quarter. DV Trading LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter worth $5,376,000. Finally, Affinity Asset Advisors LLC increased its stake in Avalo Therapeutics by 27.6% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares in the last quarter. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics News Roundup

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target to $10 from $58. The revised target still implies meaningful upside from the referenced $7.45 share price. BTIG Research rating information
• Positive Sentiment: Wedbush cut its price target to $22 from $34 but retained an Outperform rating, indicating continued confidence in Avalo’s longer-term opportunity despite near-term competitive concerns. Wedbush adjusts Avalo price target
• Neutral Sentiment: Guggenheim reaffirmed its Neutral rating, while HC Wainwright separately reaffirmed Neutral in another research update. These actions suggest limited conviction following the recent decline. Guggenheim rating information HC Wainwright rating information
• Neutral Sentiment: Trading in AVTX was temporarily halted under a volatility-related LULD pause, highlighting elevated short-term trading risk but providing no fundamental update.
• Negative Sentiment: HC Wainwright downgraded Avalo from Buy to Neutral, removing a bullish analyst stance. HC Wainwright downgrades Avalo
• Negative Sentiment: Phase III results from AbbVie in hidradenitis suppurativa appear to have raised the competitive bar for Avalo’s AVTX-009 program, weighing on the stock and contributing to broader analyst price-target reductions. AbbVie phase III data subdue Avalo shares

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.